US Neurology Editorial Board member, Stephen Silberstein (Thomas Jefferson University, Philadelphia, USA), discusses the most significant advances in the prevention and treatment of migraine in the last year.
- What do you consider the most important developments in migraine prevention and treatment in the last year? (0:04)
- What is the rationale for the use of anti epileptic drugs (AEDs) in the prevention and treatment of migraine? (0:49)
- Which AEDs do you recommend in the prevention of migraine and which might play a role in the future? (1:39)
- What is your opinion on the use of cannabinoids in the treatment of migraine? (2:13)
- What are the most exciting therapies currently in development in the field of migraine prevention and treatment? (3:19)
- Please summarize your highlights so far at this AAN meeting. (3:35)
Scientific Advisory Boards: Abide Therapeutics; Alder Biopharmaceuticals; Allergan, Inc.; Amgen; Avanir Pharmaceuticals, Inc.; Biohaven Pharmaceuticals; Cefaly; Curelator, Inc.; Dr. Reddy’s Laboratories; Egalet Corporation; GlaxoSmithKline Consumer Health Holdings, LLC; eNeura Inc.; electroCore Medical, LLC; Lilly USA, LLC; Medscape, LLC; NINDS; Satsuma Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Teva Pharmaceuticals; Theranica; and Trigemina, Inc.
Editorial Boards: Cephalalgia; Current Pain and Headache Reports; CNS Drugs; Topics in Pain Management; and Neurology.
Consultancies: Allergan; Amgen; eNeura; ElectroCore Medical; Mitsubishi Tanabe; Medtronic; Neuralieve; Pfizer; Supernus; and Teva.
Speakers’ Bureaus: Amgen; Teva; and Supernus.
Research Support, Commercial Entities (Past 2 years): GlaxoSmithKline; Allergan; Merck; Novartis; NIH; Neurolieve; MAP; Endo Now: Amgen; ElectroCore; Avanir; Allergan; Teva; and Lilly.
Research Support, Government Entities: NIH.
Research Support, Foundations and Societies: AHS and IHS.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Philadelphia, USA, May 2019.
Share this Video
Related Videos In Headache Disorders
Peter Goadsby, EAN 2020 – Visual Snow Syndrome
Delighted to interview our valued Editorial Board member Peter Goadsby (King’s College Hospital, London, UK), who shared his expert insights on visual snow syndrome and related updates presented at the 1st Virtual EAN Congress. Questions 1. What are the clinical features and spectrum of severity of visual snow syndrome, and how was it first identified? […]
Uwe Reuter, EAN 2020 – Characteristics of the HER-MES trial in episodic and chronic migraine
Uwe Reuter (Charité Universitätsmedizin Berlin, Germany) talks to us about the first head-to-head randomized, double-blind, double-dummy trial of erenumab and topiramate for the prevention of episodic and chronic migraine (ClinicalTrials.gov Identifier: NCT03828539). Questions 1. What are the unmet needs in the treatment of episodic migraine? (0:05) 2. Could you tell us a little about the […]
Hans-Christoph Diener, EAN 2020 – Chronic Migraine and Medication-Overuse Headache – PROMISE-2
Hans-Christoph Diener (Medical Faculty of the University of Duisburg-Essen, Institute for Medical Informatics, Biometry and Epidemiology, Essen, Germany) talks to us about unmet needs in the treatment of chronic migraine and medication-overuse headache, and shares expert insight on the PROMISE-2 trial, which evaluated the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!